Maria Constanza Camargo, Ph.D.
9609 Medical Center Drive
Rockville, MD 20850
H. pylori and Gastric Cancer
Gastric cancer is the third leading cause of cancer death worldwide. Dr. Camargo maintains a robust research program with a multidisciplinary team of international collaborators applying cutting edge molecular epidemiology to the study of H. pylori, premalignant and malignant gastric lesions.
As a co-PI with Charles Rabkin, M.D., senior investigator in IIB, Dr. Camargo recently launched the H. pylori Genome Project (HpGP). The HpGP will establish a large-scale international biobank of clinically annotated H. pylori strains for molecular studies addressing the role of bacterial diversity in the gastric cancer cascade. For this important initiative, Dr. Camargo has partnered with investigators from the Division of Gastroenterology at Vanderbilt University.
Dr. Camargo is currently planning a new field effort aimed to elucidate the risk factors for advanced premalignant lesions, and potential non-invasive biomarkers for risk stratification in high-risk populations in Latin America, Eastern Europe and Eastern Asia.
Esophageal Squamous Cell Carcinoma (ESCC)
As a smaller research effort, Dr. Camargo is collaborating with Sanford Dawsey, M.D. and Christian Abnet, Ph.D., M.P.H., in MEB to design and conduct studies of ESCC in endemic Asian and African populations Her research focuses on the evaluation of infections and potential biomarkers for screening.
Dr. Camargo earned an M.S. in epidemiology from the School of Public Health in Mexico, an M.H.A degree from the Pontificia Universidad Javeriana in Colombia, and a Ph.D. in public health with concentration in epidemiology from the University of Illinois at Chicago. She conducted her dissertation work at the Infections and Immunoepidemiology Branch (IIB) on the role of Epstein-Barr virus infection in gastric carcinogenesis. She joined IIB as a postdoctoral fellow in 2010 and became an Earl Stadtman Tenure-Track Investigator in the Metabolic Epidemiology Branch (MEB) in 2016.
Prior to joining NCI, Dr. Camargo was a member of the research group led by Dr. Pelayo Correa, first at Louisiana State University and then at Vanderbilt University, studying gastric cancer and its primary risk factor, Helicobacter pylori infection.
Camargo MC, Beltran M, Conde-Glez CJ, Harris PR, Michel A, Waterboer T, Carolina Flórez A, Torres J, Ferreccio C, Sampson JN, Pawlita M, Rabkin CS. Serological response to Helicobacter pylori infection among Latin American populations with contrasting risks of gastric cancer. Int J Cancer. 2015;137(12):3000-5.
Camargo MC, Kim WH, Chiaravalli AM, Kim KM, Corvalan AH, Matsuo K, Yu J, Sung JJ, Herrera-Goepfert R, Meneses-Gonzalez F, Kijima Y, Natsugoe S, Liao LM, Lissowska J, Kim S, Hu N, Gonzalez CA, Yatabe Y, Koriyama C, Hewitt SM, Akiba S, Gulley ML, Taylor PR, Rabkin CS. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut. 2014;63(2):236-43.
Camargo MC, Murphy G, Koriyama C, Pfeiffer RM, Kim WH, Herrera-Goepfert R, Corvalan AH, Carrascal E, Abdirad A, Anwar M, Hao Z, Kattoor J, Yoshiwara-Wakabayashi E, Eizuru Y, Rabkin CS, Akiba S. Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis. Br J Cancer. 2011;105(1):38-43.
Camargo MC, Anderson WF, King JB, Correa P, Thomas CC, Rosenberg PS, Eheman CR, Rabkin CS. Divergent trends for gastric cancer incidence by anatomical subsite in US adults. Gut. 2011;60(12):1644-9.
Anderson WF, Camargo MC, Fraumeni JF Jr, Correa P, Rosenberg PS, Rabkin CS. Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA. 2010;303(17):1723-8.
Related Scientific Focus Areas
Microbiology and Infectious Diseases
Genetics and Genomics
This page was last updated on April 13th, 2017